My New York City practice has been a refractive-only practice for more than 25 years, offering the full range of FDA-approved vision correction surgery options, from lasers to IOLs.The rate-limiting ...

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...

Successful explantation of a corneal microlens for presbyopia and implantation of a trifocal IOL in a patient who developed ...

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

Most people have a relative, friend or neighbor who has had to deal with a cataract. Nearly 24.5 million Americans age 40 or older are affected by cataracts, and it’s the leading cause of blindness ...

The TECNIS Odyssey IOL addresses a significant unmet need for cataract patients seeking greater spectacle independence., Bizz ...

Among children who underwent unilateral cataract removal in infancy, risk of glaucoma-related adverse events continues to increase with longer follow-up and is not associated with primary intraocular ...

Johnson & Johnson (NYSE:JNJ) received FDA approval for its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract patients. The lens is described as the first of its kind in the ...

Johnson & Johnson’s TECNIS Odyssey IOL launched in India, offering a full visual range and high contrast to reduce spectacle dependency.